RegulationAccelerated Approval (United States), Commissioner's National Priority Voucher (United States), Breakthrough Therapy (China), Priority Review (United States), Conditional marketing approval (Canada), Priority Review (China)

Structure/Sequence

Sequence Code 50953

Source: *****

644

Clinical Trials associated with Semaglutide (Novo Nordisk)

NCT07586150

/ Not yet recruitingNot ApplicableIIT

Personalised Pharmaco-Lifestyle Interventions for Severe Mental Illnesses Enhanced by Digital Health and Immersive Technologies

This randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar disorder, or major depressive disorder. Participants will be randomized to either a modular individualized intervention program or a structured psychoeducation control condition. The individualized intervention may include physical exercise, an anti-inflammatory diet, sleep intervention, social prescribing, semaglutide for eligible participants with overweight or obesity, and optional closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms. The primary outcome is change in the SF-36 Mental Component Summary score from baseline to Month 3.

Start Date01 Oct 2028

Sponsor / Collaborator

Ludwig-Maximilians-Universität München

NCT07430332

/ Not yet recruitingPhase 2IIT

Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

Start Date01 Sep 2027

Sponsor / Collaborator

Children's Hospital & Medical Center

NCT07614412

/ Not yet recruitingPhase 2IIT

Recombinant Zoster Vaccine (Shingrix) and GLP-1 Receptor Agonist for the Preservation of Beta-Cell Function in Adults With Recent-Onset Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial.

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by progressive destruction of pancreatic beta cells mediated by autoreactive T lymphocytes, resulting in absolute insulin deficiency. Preservation of residual beta-cell function at the time of diagnosis is a critical therapeutic window, as even marginal endogenous insulin secretion - reflected by detectable C-peptide levels - is associated with improved glycemic control, reduced hypoglycemia burden, and decreased long-term vascular complication rates.
This study evaluates the hypothesis that combinatorial immunomodulation - using the AS01B adjuvant system within the Recombinant Zoster Vaccine (RZV; Shingrix, GSK) alongside metabolic and cytoprotective support via a GLP-1 receptor agonist (semaglutide) - can synergistically preserve residual beta-cell function in adults within 100 days of T1D diagnosis. The AS01B adjuvant system activates innate immune pathways that promote regulatory T-cell (Treg) expansion and shift the immunological milieu toward tolerance, while GLP-1 receptor agonism provides direct beta-cell cytoprotection, reduces glucotoxicity, and may suppress autoimmune cytokine signaling.
SHIELD-T1D is a randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial enrolling 240 adults (18-50 years) diagnosed with T1D within 100 days, with confirmed residual beta-cell function (stimulated C-peptide ≥0.2 nmol/L). Participants are randomized 1:1:1:1 to one of four arms: (1) Shingrix alone, (2) Semaglutide alone, (3) Shingrix + Semaglutide combination, or (4) dual placebo. The primary endpoint is change in 2-hour stimulated C-peptide AUC during a Mixed Meal Tolerance Test (MMTT) from baseline to 12 months.
This phase II randomized, double-blind, placebo-controlled multicenter trial will evaluate the efficacy and safety of the recombinant zoster vaccine (Shingrix) and a glucagon-like peptide-1 (GLP-1) receptor agonist, alone and in combination, for preservation of residual beta-cell function in adults with recent-onset type 1 diabetes. The working hypothesis is that combining AS01 adjuvant-mediated immunomodulation with the metabolic and cytoprotective actions of a GLP-1 receptor agonist will provide dual protection for pancreatic beta cells, slowing autoimmune destruction and improving functional insulin secretion compared with placebo.

Start Date01 Jan 2027

Sponsor / Collaborator-

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

381

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

01 Jul 2026·FREE RADICAL BIOLOGY AND MEDICINE

Semaglutide ameliorates aortic endothelial cell dysfunction in sarcopenia through the SIRT1/cGAS-STING signaling axis

Article

Author: Zhang, Xin ; Wang, Xinglin ; Huang, Ziteng ; Ye, Xiangming ; Qiao, Gan ; Huang, Ting ; Sun, Weiyue ; Yang, Ping ; Wu, Haoran ; Liu, Yang ; Tang, Linyi ; Li, Liyun

Sarcopenia associated with aging is a significant health issue affecting the quality of life in the elderly, yet research on effective treatments remains insufficient. This study aims to investigate the therapeutic effects and mechanisms of Semaglutide (Sema) in D-gal-induced aging-related sarcopenia and endothelial cell senescence. By establishing D-gal-induced mouse models and human aortic endothelial cells (HAEC), and employing methods such as grip strength tests, ELISA, and immunohistochemistry, the therapeutic efficacy and underlying mechanisms of Sema were systematically evaluated. The results demonstrated that Sema significantly improved grip strength in D-gal-induced mice and reduced serum levels of IL-1β and TNF-α, indicating its protective role against sarcopenia. Furthermore, Sema effectively alleviated endothelial cell senescence and improved endothelial function, with the underlying mechanisms potentially involving the upregulation of SIRT1 expression and inhibition of the cGAS-STING signaling pathway activation. This study systematically reveals, for the first time, the therapeutic potential of Sema in aging-related sarcopenia, especially its protective effect against aortic endothelial senescence, providing new perspectives and evidence for its clinical application.

01 Jul 2026·International journal of social determinants of health and health services

Ozempic and Wegovy Meet Congress: Political Economy Without Critique and Sociology Without Society

Article

Author: Loeppky, Rodney

In the fall of 2024, a U.S. Senate Hearing on the high price of Novo Nordisk's prescription drugs Ozempic and Wegovy underlined some of the deepest challenges in the U.S. health care system. This article utilizes critical approaches to both political economy and sociological discussions of medicalization as a means to address these challenges. Market-led organization and medicalization underlie not only these products’ pricing, but also wider issues of cost control and health care organization. Congressional debate tends to either attribute blame on individual corporate actors, largely sidestepping larger structural issues, or defend industry and profit-oriented care, deflecting blame for high costs on the lifestyle choices of individual Americans. The article reestablishes an interrelation between critical political economy and medicalization, calling for a reorientation of health purchasing in the United States, along the lines of a single payer system that would, by necessity, interrogate the value of evolving drug (and other medical) provision for American society. This argument has strong practical political implications, potentially enabling policymakers to approach the emergence of ‘wonder’ drugs like Ozempic/Wegovy on terms that matter to both patients and U.S. society—price, medical necessity, access, and overall health care costs.

01 Jun 2026·BIOETHICS

Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large

Article

Author: Minerva, Francesca

ABSTRACT:

This paper explores the ethical implications of emerging weight‐loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications promise significant benefits, including improved individual health outcomes, reduced healthcare costs and, potentially, reduced environmental harms. However, their widespread adoption raises various concerns, such as unknown long‐term side effects, the exacerbation of weight‐based discrimination, and the reinforcement of socioeconomic disparities. The paper argues that, with robust regulatory frameworks in place, the potential benefits of these medications are likely to outweigh the risks. Nonetheless, ongoing monitoring of their effect on individuals and society at large remains essential.

3,178

News (Medical) associated with Semaglutide (Novo Nordisk)

17 Jul 2026

·www.prnewswire.com

Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory Concerns

CU Anschutz researchers found the compounded GLP-1 market remains robust after FDA shortages ended, with some products supplied by pharmacies lacking sterile compounding licenses or with recent disciplinary histories AURORA, Colo., July 17, 2026 /PRNewswire/ - Despite the end of federal shortages of popular GLP-1 weight-loss medications, the market for compounded alternatives remains strong – and some patients may unknowingly be receiving products from pharmacies with concerning regulatory histories, according to new research from the University of Colorado Anschutz. Published today in JAMA Health Forum, the study found that many weight-loss clinics and medical spas continue to sell compounded versions of GLP-1 medications such as semaglutide and tirzepatide. Researchers also identified suppliers that lacked licenses required for sterile compounding or had recently been subject to disciplinary actions related to sterile compounding practices. "Our findings suggest this market didn't shrink after the shortages ended as many expected," said lead author Michael J. DiStefano, PhD, MBE, assistant professor at the University of Colorado Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences. "Instead, it has remained remarkably robust, raising important questions about how these products are regulated and how patients can know whether they're receiving medications that meet appropriate quality standards." Compounded GLP-1 drugs expanded rapidly during nationwide shortages of Wegovy and Zepbound, when federal regulations temporarily allowed pharmacies to compound copies of medications in short supply. Researchers wanted to know what happened after those shortages ended and the FDA resumed enforcement against routine copies of commercially available products. DiStefano and colleagues examined brick-and-mortar weight-loss clinics and medical spas, an area that has received less scrutiny than online telehealth despite serving many patients. Using a "secret shopper" approach, researchers contacted businesses in Oklahoma and West Virginia to ask what products were available, how patients were monitored and where the medications were sourced. The team identified 75 clinics and medical spas offering compounded GLP-1 medications. Instead of seeing the market disappear, the researchers found evidence that many compounded products now include added ingredients, such as vitamin B12, which may be presented as individualized formulations. "One concern is whether we're seeing clinically meaningful personalization or changes that primarily allow compounded products to remain on the market," DiStefano said. "For many of these added ingredients, we simply don't have good evidence showing they improve safety or effectiveness." Additionally, among the 23 compounding pharmacies supplying these businesses, four lacked licenses for sterile compounding, while several had recent disciplinary actions or FDA warning letters related to sterile compounding practices. DiStefano emphasized that compounded GLP-1 medications have helped expand access for patients who cannot afford brand-name drugs or whose insurance does not cover obesity treatment. However, he said patients should not have to choose between affordability and quality. "This market has grown so large and diffuse that it's difficult for regulators to oversee every pharmacy supplying these medications," he said. "Our findings suggest there's a need for regulatory innovation that preserves access while giving patients greater confidence that the products they're receiving are safe and appropriately manufactured." The researchers hope the findings encourage clinicians and patients to ask more questions about where compounded medications originate and whether the pharmacies producing them meet appropriate standards for sterile compounding. Key Takeaways: Compounded GLP-1 medications remain widely available at many weight-loss clinics and medical spas despite the end of FDA shortages. Some clinics reported sourcing medications from pharmacies with regulatory concerns, including a lack of sterile compounding licenses or recent disciplinary actions. The study did not evaluate the safety or quality of the medications. It examined how compounded GLP-1 products are marketed and sourced. Researchers say patients should not have to choose between affordability and quality and call for greater transparency and oversight while preserving access. Frequently Asked Questions: What did the study find? A University of Colorado Anschutz study published in JAMA Health Forum found that many weight-loss clinics and medical spas continue to offer compounded GLP-1 medications after FDA shortages ended. The researchers also identified some suppliers that lacked sterile compounding licenses or had recent disciplinary actions related to sterile compounding practices. Does this study show that compounded GLP-1 medications are unsafe? No. The University of Colorado Anschutz study did not evaluate the safety, quality or effectiveness of compounded GLP-1 medications. Instead, it examined how these medications are marketed and sourced by weight-loss clinics and medical spas. Why is this study important? The study highlights the need for greater transparency and oversight in the growing market for compounded GLP-1 medications. It also emphasizes that patients should not have to choose between affordable obesity treatment and confidence in the quality of their medications. Why are patients still using compounded semaglutide and tirzepatide? Many patients use compounded semaglutide and tirzepatide because brand-name GLP-1 medications can be expensive or are not covered by insurance. Compounded medications have expanded access to obesity treatment for many people. What should patients know before using compounded GLP-1 medications? Patients should talk with their healthcare provider about why a compounded GLP-1 medication is recommended, where it is produced, and whether the pharmacy meets appropriate sterile compounding standards. Patients should not stop taking prescribed medication based on this study alone without consulting their healthcare provider. Contact: Kelsea Pieters, CU Anschutz [email protected], Phone: (804) 314-1360 SOURCE University of Colorado Anschutz 21% more press release views with Request a Demo

16 Jul 2026

·health.ucsd.edu

GLP-1 Shows Promise for Patients with Advanced Fatty Liver Disease

Researchers at University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis. The study results, published in the July 15, 2026, online edition of The Lancet Gastroenterology & Hepatology, address a major unmet need for people with metabolic dysfunction–associated steatohepatitis (MASH), a serious form of fatty liver disease that can lead to cirrhosis, liver failure, and the need for transplantation. "This is the first clinical trial to demonstrate that semaglutide may improve liver fibrosis in patients with advanced MASH, including those with compensated cirrhosis," said Rohit Loomba, MD, senior author of the study, gastroenterologist and hepatologist at UC San Diego Health and chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine. "The results with semaglutide alone are encouraging and suggest a potential new treatment option for a group of patients who previously had very few." The Phase II trial followed about 700 adults with biopsy-confirmed MASH and moderate to advanced liver scarring, including participants who had already developed early cirrhosis. Researchers tested whether combining zalfermin, an experimental medicine designed to improve the body's metabolism, with GLP-1 receptor agonist, could reverse liver fibrosis more effectively than either treatment alone. Rohit Loomba, MD, senior author of the study, gastroenterologist and hepatologist at UC San Diego Health and chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine. Photo credit: UC San Diego Health While the combination therapy did not outperform the placebo, GLP-1 on its own showed a statistically significant improvement in liver scarring without worsening underlying liver inflammation, even among patients with the most advanced disease. MASH affects millions of people worldwide and is one of the fastest growing causes of liver failure and liver transplantation. As the disease progresses, scar tissue builds in the liver, eventually impairing its ability to function. Until now, patients with cirrhosis caused by MASH have often been excluded from clinical trials and have had limited treatment options, making the findings particularly noteworthy. Loomba is also the founding director of the UC San Diego MASLD Research Center, where his multidisciplinary team is dedicated to performing leading-edge translational research in all aspects of MASLD. The study also found that non-invasive blood tests and imaging measures reflected treatment-related improvements more clearly than liver biopsies. This could eventually help reduce reliance on biopsies, which are invasive and difficult to repeat, and make it easier for clinicians to monitor patients over time. The researchers emphasize that larger clinical trials focused specifically on patients with cirrhosis are needed to confirm these results. They also note that other drugs in the same class as zalfermin, designed slightly differently, may still hold promise and deserve further study. "These findings strengthen the need to continue studying semaglutide and other metabolic therapies in advanced liver disease," Loomba said. "Our goal is to move the field toward effective, accessible treatments that can slow or even reverse liver damage before patients reach liver failure." Co-authors include Jacob George, Westmead Institute for Medical Research; Laurent Castera, Unviersite Paris Cite; Sven Francque, Antwerp University Hospital; Eric Lawitz, University of Texas Health; Lise Lotte Gluud, Copenhagen University Hospital; Ahsan Shoeb, Jesper Ole Clausen, Birgitte Andersen, and Anna Bille Larsen, Novo Nordisk. Funding support for the study came, in part, from Novo Nordisk. Disclosures: Rohit Loomba, MD, is a consultant or advisory board member for Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Terns Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes. Loomba is also co-founder of Liponexus, Inc.

Phase 2Clinical Result

16 Jul 2026

·www.genohopebio.com

Sun Pharma Receives Approval To Manufacture And Market Generic Semaglutide in South Africa

Jul 16, 2026 View: 104 Leave a message Mumbai, India, July 15, 2026 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) announced that it has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing. "South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals," said Aalok Shanghvi, Chief Operating Officer, Sun Pharma. South Africa faces a growing burden of type 2 diabetes, driven in part by rapid urbanization and changing lifestyles. This rising prevalence places significant pressure on patients and healthcare services. Improving access to effective therapies is therefore an important component of addressing this national health challenge. GenoHope Biotech Ltd. A leading manufacturer of GLP-1 API Approal by FDA Welcome any Inquiry WhatsApp/Tel:+8613833133635 Email:info@genohopebio.com Send Inquiry

Drug Approval

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Diseases	United Kingdom	Novo Nordisk A/S	01 Apr 2026
Fibrosis, Liver	United States	Novo Nordisk, Inc.	22 Dec 2025
Pulmonary Fibrosis	Canada	Novo Nordisk Canada, Inc.	21 Dec 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk, Inc.	15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk A/S	15 Aug 2025
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Cardiovascular Diseases	United States	Novo Nordisk, Inc.	08 Mar 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Norway	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04707469 (PIONEER PLUS, ADA2026)	Phase 3	Diabetes Mellitus, Type 2	262	Oral Semaglutide 14 mg	fsolirbpkf(hfazrmfjzg) = kqehlyyqep fwatsyqeou (jupoqdvzow ) View more	Positive	20 Jun 2026
NCT04707469 (PIONEER PLUS, ADA2026)	Phase 3	Diabetes Mellitus, Type 2	262	Oral Semaglutide 25 mg	fsolirbpkf(hfazrmfjzg) = hecgfcdobr fwatsyqeou (jupoqdvzow )	Positive	20 Jun 2026
ADA2026	Not Applicable	Diabetes Mellitus, Type 2	45	Semaglutide (Kidney Transplant Recipients + Type 2 Diabetes)	hbavzsvbui(nhoamgxymi) = fkqbapbohx osfhltkezo (fcsxlkdfsy )	Positive	20 Jun 2026
SELECT (ADA2026)	Phase 3	Asthma blood high-sensitivity C-reactive protein [hsCRP]	1,190	Semaglutide 2.4 mg	qmeaiihluj(sgabdxgqqw) = neogubakmo slckmohvjo (oyocwbiuwy ) View more	Positive	20 Jun 2026
SELECT (ADA2026)	Phase 3	Asthma blood high-sensitivity C-reactive protein [hsCRP]	1,190	Placebo	qmeaiihluj(sgabdxgqqw) = jgwicdfdjq slckmohvjo (oyocwbiuwy ) View more	Positive	20 Jun 2026
NCT05537233 (ADJUST-T1D, ADA2026)	Phase 3	Diabetes Mellitus, Type 1	72	Semaglutide	gwbcjyxaui(fcclszscmr) = riadpwhupq sfbtcqengp (efvbcjwahe )	Positive	20 Jun 2026
NCT05537233 (ADJUST-T1D, ADA2026)	Phase 3	Diabetes Mellitus, Type 1	72	Placebo	gwbcjyxaui(fcclszscmr) = rarczodumt sfbtcqengp (efvbcjwahe )	Positive	20 Jun 2026
PIONEER PLUS (ADA2026)	Phase 3	Diabetes Mellitus, Type 2	1,012	Oral Semaglutide 50 mg	stwnubbigh(ggwfrpbcjd) = arszcelgtw ycihtvtebi (yjevmsxxkl )	Positive	20 Jun 2026
ADA2026	Not Applicable	Obesity	177	Oral Semaglutide (Rybelsus) (Diabetes)	ioigknmuyf(hvvmiwjwln) = jfnbnrptqz qowqbjdksa (cuokiuojjs ) View more	Positive	20 Jun 2026
ADA2026	Not Applicable	Diabetes Mellitus, Type 2	66	Insulin Icodec + Semaglutide (Uncontrolled Type 2 Diabetes)	lmlegwaqlm(luzqsrzixe) = improved significantly from 54.8±23.3% at baseline to 78.1±18.9% (95% CI 9.5-25.5, P<0.001) fmbwlqxlmm (ekvdbhiekp ) View more	Positive	20 Jun 2026
NCT04707469 (PIONEER PLUS, ADA2026)	Phase 3	Diabetes Mellitus, Type 2	606	Oral Semaglutide 25mg	jxfjgyoxue(tbpylecfcs) = eiocrxldjs aybmubcsno (cdyjzoamua ) View more	Positive	20 Jun 2026
NCT04707469 (PIONEER PLUS, ADA2026)	Phase 3	Diabetes Mellitus, Type 2	606	Oral Semaglutide 14mg	jxfjgyoxue(tbpylecfcs) = yebaoropkf aybmubcsno (cdyjzoamua ) View more	Positive	20 Jun 2026
GAROS (ADA2026)	Not Applicable	Obesity	1,091	Oral Semaglutide 42 mg/day	itzpgcuyqd(moqzuzayyj) = liwzybugub ryzpjgmfrj (jculavuhxg ) View more	Positive	20 Jun 2026
ADA2026	Not Applicable	Diabetes Mellitus, Type 2	104	Semaglutide 0.5-1.0 mg weekly (Type 2 Diabetes)	fkdszhxbxg(sdzctclkul) = tsmfjbxjzh vzkyfliohl (ywwmubyxid ) View more	Positive	20 Jun 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis